Brimonidine for Intraoperative Hemostasis
Dermatochalasis of Eyelid, Ptosis, Eyelid, Ectropion
About this trial
This is an interventional treatment trial for Dermatochalasis of Eyelid
Eligibility Criteria
Inclusion Criteria:
- Above the age of 18
- Ophthalmic conditions requiring oculoplastic surgery
Exclusion Criteria:
- Known allergy or adverse effects to brimonidine
- Hypotony
- Acute ophthalmic infection
- History of hypotension
- Orthostatic hypotension
- Pregnancy
- History of Central Nervous System (CNS) depression from medication use
- Thrombotic disorders
- Asymmetrical oculoplastic conditions that may interfere with tear drainage (e.g. unilateral NLDO)
- Current use of brimonidine
Sites / Locations
- University of LouisvilleRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Brimonidine intervention
Control Arm
We will compare hemostasis between 2 surgical sides of the same patient. One side will be randomized to receive Brimonidine (0.15% or 0.2%) in addition to standard hemostasis measures, while the other side will receive only standard hemostasis measures (preoperative discontinuation of blood thinners, preoperative injection of lidocaine with epinephrine).
We will compare hemostasis between 2 surgical sides of the same patient. One side will be randomized to receive Brimonidine (0.15% or 0.2%) in addition to standard hemostasis measures, while the other side will receive only standard hemostasis measures (preoperative discontinuation of blood thinners, preoperative injection of lidocaine with epinephrine).